Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 4/20 | 0.36 |
| ▸ | NMBR | P28336 | 1/20 | 0.35 |
| ▸ | GRPR | P30550 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2258036 | 1.00 | TACR1 (0.39) | TACR1TGFBR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2259904 | 0.84 | MAPT (0.45) | TGFBR1TP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL2263324 | 0.83 | MAPT (0.50) | MAPT | |
| SCHEMBL2254827 | 0.83 | MAPT (0.59) | TACR1TP53MAPTSMN1; SMN2LMNA | |
| SCHEMBL2258570 | 0.78 | MTNR1A (0.49) | MAPT | |
| SCHEMBL2260465 | 0.76 | KMT2A (0.50) | TP53MAPTSMN1; SMN2LMNATHRB | |
| SCHEMBL2260468 | 0.76 | KMT2A (0.50) | TP53MAPTSMN1; SMN2LMNATHRB | |
| SCHEMBL2258149 | 0.75 | TGFBR1 (0.46) | TGFBR1 | |
| SCHEMBL2257815 | 0.75 | TRPV1 (0.44) | TGFBR1 | |
| SCHEMBL12361506 | 0.75 | TGFBR1 (0.49) | TGFBR1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | TACR1 353/4885TGFBR1 481/4885TP53 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.